Powerful new technology may lead to novel therapies to prevent vision loss, blindness in those with diseases of the retina
Boston, Mass. — A research team from the Schepens Eye Research Institute of Massachusetts Eye and Ear has successfully prevented mice from developing angiogenesis of the retina—the sensory tissue at the back of the eye—using gene-editing techniques with CRISPR-Cas9. Angiogenesis causes vision loss and blindness and is a feature of several degenerative eye conditions, including proliferative diabetic
Patrick Oellers, MD, is the inaugural recipient of the Thomas J. Madden Fellowship in Retina at Mass. Eye and Ear. Patrick is completing his first year as a Retina Surgery Fellow. The fellowship was created to support a clinical or research fellow while honoring the legacy of Thomas J. Madden who passed away in 2015. Tom played an instrumental role in securing the successful outcome of patent-related litigation resulting in the landmark $126M judgment for Mass. Eye and Ear against QLT, Inc. and Novartis in 2009. The award has enabled major
Findings may lead to the development of therapies to prevent damage to the retina, the light-sensitive tissue at the back of the eye.
Boston, Mass. — Chemical eye burns caused by alkali agents not only injure the front of the eye — the cornea, where the contact takes place — but also cause widespread damage to the light-sensitive tissue at the back of the eye (the retina) as well, often leading to optic nerve damage and glaucoma. In a report
Boston, Mass. — It’s the part of the eye exam everyone hates: the pupil-dilating eye drops. The drops work by opening the pupil and preventing the iris from constricting in response to light and are often used for routine examination and photography of the back of the eye. The drops sting, can take up to 30 minutes to work, and cause blurry vision for several hours afterwards, often making them inconvenient for both patient and doctor.
Now, researchers at Massachusetts Eye and Ear/Harvard Medical School and the University